Shire Development, LLC v. Watson Pharmaceuticals, Inc., No. 13-1409 (Fed. Cir. Mar. 28, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

The plaintiffs -appellees (collectively, Shire) own U.S. Patent No. 6,773,720, which claims a controlled -release oral pharmaceutical composition for treating inflammato- ry bowel diseases. Shire markets these oral pharmaceuti- cal compositions under the brand name LIALDA® . After the defendants-appellants (collectively, Watson) submi t- ted an Abbreviated New Drug Application (ANDA) see k- ing approval to s ell the bioequivalent of LIALDA®, Shire sued for infringement of the ’720 patent.